Author:
Reynolds Catherine J.,Swadling Leo,Gibbons Joseph M.,Pade Corinna,Jensen Melanie P.,Diniz Mariana O.,Schmidt Nathalie M.,Butler David,Amin Oliver E.,Bailey Sasha N. L.,Taylor Stephen,Jones Jessica,Jones Meleri,Jason Lee Wing-Yiu,Rosenheim Joshua,Chandran Aneesh,Joy George,Di Genova Cecilia,Temperton Nigel,Lambourne Jonathan,Cutino-Moguel Teresa,Andiapen Mervyn,Fontana Marianna,Smit Angelique,Semper Amanda,O’Brien Ben,Chain Benjamin,Brooks Tim,Manisty Charlotte,Treibel Thomas,Moon James C,Noursadeghi Mahdad,Altmann Daniel M.,Maini Mala K.,McKnight Aine,Boyton Rosemary J., ,
Abstract
AbstractStudies of adaptive immunity to SARS-CoV-2 include characterisation of lethal, severe and mild cases1-8. Understanding how long immunity lasts in people who have had mild or asymptomatic infection is crucial. Healthcare worker (HCW) cohorts exposed to and infected by SARS-CoV-2 during the early stages of the pandemic are an invaluable resource to study this question9-14. The UK COVIDsortium is a longitudinal, London hospital HCW cohort, followed from the time of UK lockdown9,10 ; weekly PCR, serology and symptom diaries allowed capture of asymptomatic infection around the time of onset, so duration of immunity could be tracked. Here, we conduct a cross-sectional, case-control, sub-study of 136 HCW at 16-18 weeks after UK lockdown, with 76 having had laboratory-confirmed SARS-CoV-2 mild or asymptomatic infection. Neutralising antibodies (nAb) were present in 90% of infected HCW sampled after the first wave; titres, likely to correlate with functional protection, were present in 66% at 16-18 weeks. T cell responses tended to be lower in asymptomatic infected HCW than those reporting case-definition symptoms of COVID-19, while nAb titres were maintained irrespective of symptoms. T cell and antibody responses were discordant. HCW lacking nAb also showed undetectable T cells to Spike protein but had T cells of other specificities. Our findings suggest that the majority of HCW with mild or asymptomatic SARS-CoV-2 infection carry nAb complemented by multi-specific T cell responses for at least 4 months after mild or asymptomatic SARS-CoV-2 infection.
Publisher
Cold Spring Harbor Laboratory